Notably, patients who received niacin showed a trend towards increased NAD in leukocytes post-treatment while the same was not evident in tumors, suggesting the possibility of prominent NAPRT1 levels in the normal leukocytes compared with the tumors (Supplemental Fig.
← all excerpts
First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.
1
—
—